Key result
Atrial septostomy serves as an effective palliative treatment for patients with end-stage pulmonary arterial hypertension, significantly improving hemodynamics and quality of life while awaiting lung transplantation.
Why the study?
PAH is an irreversible, life-threatening condition progressing to right heart failure, and while atrial septostomy provides palliative relief and a buffer to lung transplantation, it does not fundamentally alter malignant outcomes.
Answers are grounded in this paper and cite their sources.
Atrial septostomy remains a viable palliative option and bridge to transplantation for patients with severe, medically refractory pulmonary arterial hypertension by improving systemic blood flow despite reducing systemic oxygen saturation.
Pulmonary arterial hypertension (PAH) is currently an irreversible disease, with many patients eventually progressing to right heart failure, severely affecting their quality of life and posing a life-threatening risk. Percutaneous atrial septostomy was first performed in infants with transposition of the great arteries in 1966. Since then, it has been used as a palliative treatment for patients with end-stage PAH, significantly improving their quality of life and providing a buffer period while waiting for lung transplantation. However, this method does not fundamentally alter the malignant outcomes of patients with PAH. This study reviews the development and evolution of atrial septostomy, summarises various emerging technologies, and systematically explains the mechanisms, efficacy, and prognosis of palliative treatment in patients with PAH. Furthermore, new ideas for this treatment approach are proposed with the hope that it will bring more benefits to patients with PAH in the future and be more fully utilised.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2025) conducted a review in Pulmonary arterial hypertension (PAH). Atrial septostomy was evaluated. Atrial septostomy serves as an effective palliative treatment for patients with end-stage pulmonary arterial hypertension, significantly improving hemodynamics and quality of life while awaiting lung transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: